




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
NephroticSyndromeOverviewDefinitionnephroticsyndromePathologyofprimarynephroticsyndromeandclinicalfeaturesDiagnosisandDifferentialdiagnosisComplicationsTreatmentofprimarynephroticsyndromeSecondarynephroticsyndrome-Diabeticnephropathy-Lupusnephritis-RenalAmyloidosis-HBV-associatednephropathy
ThemostcommonsyndromeofkidneydiseaseAcuteNephriticsyndromeNephroticsyndromeAsymptomaticurinaryabnormalitiesAcuterenalfailureorRapidlyprogressiverenalfailureChronickidneydisease(Table1)
(一)急性腎炎綜合征(二)腎病綜合征(三)無癥狀性尿檢異常(四)急性及急進(jìn)性腎衰竭綜合征(五)慢性腎臟病(表1)2012KDIGO指南更新再強(qiáng)調(diào):
蛋白尿水平及GFR是評估CKD進(jìn)展的重要指標(biāo)圖注:綠色:低風(fēng)險(如沒有其他腎臟疾病的標(biāo)志物);黃色:中度增加風(fēng)險;桔色:高風(fēng)險;紅色:非常高風(fēng)險持續(xù)性蛋白尿診斷標(biāo)準(zhǔn)和范圍Kidneyinter.,Suppl.2012;2:337–414.
Pathophysiology:ProteinuriaFigure3.
lessthan150mg/24
hoursInnormalconditionalittleproteincanbeavailableinurineThreemainmechanismofproteinuriaGlomerular(increasefiltration)Tubular(decreasereabsorption)Overflow(markedoverproduction ofaparticularproteinNephroticSyndromeItisnotadiseasebutagroupofsignsandsymptomspresentswithedemaproteinuriausually>3.5g/24hrsserumalbumin<30g/Lotherfeatures:hyperlipidaemia,andhypercoaguablestatePathophysiologyPathologyofPrimaryNephtoticSyndromeMinimalChangeDiseaseMesanginalProliferativeGlomerulonephritisFocalSegmentalGlomerulosclerosisMembranousNephropathyMembranoproliferativeGlomerulonephritis(MPGN)NormalglomerulusLightmicrographofanormalglomerulus.Thereareonly1or2cellspercapillarytuft,thecapillarylumensareopen,thethicknessoftheglomerularcapillarywall(longarrow)issimilartothatofthetubularbasementmembranes(shortarrow),andthemesangialcellsandmesangialmatrixarelocatedinthecentralorstalkregionsofthetuft(arrows).CourtesyofHelmutGRennke.
Lightmicrographofanessentiallynormalglomerulusinminimalchangedisease.Thereareonly1or2cellspercapillarytuft,thecapillarylumensareopen,thethicknessoftheglomerularcapillarywallsisnormal,andthereisneitherexpansionnorhypercellularityinthemesangialareasinthecentralorstalkregionsofthetuft(arrows).CourtesyofHelmutGRennke.
MinimalchangediseaseMinimalchangediseaseMinimalchangediseaseElectronmicrographofanormalglomerularcapillaryloopshowingthefenestratedendothelialcell(Endo),theglomerularbasementmembrane(GBM),andtheepithelialcellswithitsinterdigitatingfootprocesses(arrow).TheGBMisthinandnoelectrondensedepositsarepresent.Twonormalplateletsareseeninthecapillarylumen.CourtesyofHelmutRennke,MD.
NormalglomerulusElectronmicrographinminimalchangediseaseshowinganormalglomerularbasementmembrane(GBM),noimmunedeposits,andthecharacteristicwidespreadfusionoftheepithelialcellfootprocesses(arrows).CourtesyofHelmutRennke,MD.
MinimalchangediseaseMinimalChangeDiseaseMostfrequentcauseofnephroticsyndromeinchildren.generalizededemawithnormalrenalfunctionandselectiveproteinuria.Hematuriaisabsentandpatientsarenormotensive.LM-Normal.IF-Negative.EM-footprocessfusion.Respondsreadilytosteroids,althoughrelapsesarecommon.Thelongtermprognosisisexcellent.SteroidresistantpatientsmayprogresstoFSGS.
FocalSegmentalGlomerulosclerosis
Occursinchildrenandadults,representingabout10%ofallcasesofnephroticsyndrome.Hematuria,hypertension,andnonselectiveproteinuriamaybepresent.LM:focalsegmentalglomerularsclerosis(hyalinosis)isseen.IF:IgMandC3inthesescleroticareas.Oftenpoorlyresponsivetosteroids.Childrenmayrespondmorefavorablythanadults.
Figure6.Lightmicroscopicappearancesinfocalsegmentalglomerulosclerosis.Segmentalscarswithcapsularadhesionsinotherwisenormalglomeruli.
MembranousnephropathyMostcommoncauseinadults.Especiallyelderlypeople.LM:glomerularbasementmembranethickeningwithnocellularproliferation.IF:granulardepositsofIgGandC3alongthebasementmembrane.EM:thickeningofbasementmembraneandfootprocessfusion.Theprognosisisvariable.Spontaneousremissionsoccurinsomecaseswhereasothersprogressslowlytochronicrenalfailure.Steroidsandimmunesuppressiveagentsmaybeeffectiveinretardingtheprogressiontorenalfailure.
ImmunofluorescencemicroscopyofMN(IgG)MembranousnephropathyLightmicrographofmembranousnephropathy,showingdiffusethickeningoftheglomerularbasementmembrane(longarrows)withessentiallynormalcellularity.Notehowthethicknessoftheglomerularcapillarywallsismuchgreaterthanthatoftheadjacenttubularbasementmembranes(shortarrow).Therearealsoareasofmesangialexpansion(asterisks).Immunofluorescencemicroscopy(showinggranularIgGdeposition)andelectronmicroscopy(showingsubepithelialdeposits)aregenerallyrequiredtoconfirmthediagnosis.CourtesyofHelmutRennke,MD.
ElectronmicrograpsshowsstageIImembranousnephropathy.Electrondensedeposits(D)arepresentinthesubepithelialspaceacrosstheglomerularbasementmembrane(GBM)andundertheepithelialcells(Ep).Newbasementmembraneisgrowingbetweenthedeposits,leadingtoaspikeappearanceonsilverstain.CourtesyofHelmutRennke,MD.
MembranousnephropathyComplicationsInfectionCoagulationdisordersAcuterenalfailureProteinmalnutritionanddyslipidemiaTheimpairmentofnormaldefenseisnotwellunderstood;
LowlevelsofimmunoglobulinGInfectionPatientswiththenephroticsyndromearesusceptibletoinfection,whichwastheleadingcauseofdeathinchildrenwiththenephroticsyndromebeforeantibioticsbecameavailable.Pneumococcalinfections,especiallyperitonitis,wereparticularlycommonComplicationsdecreasedlevelsofantithrombin
,plasminogen(urinarylosses),
hyperfibrinogenemiaincreasedplateletactivation
10to40percentofpatientsdevelopvenousthromboemboli,particularlydeepveinandrenalveinthrombosis
Renalveinthrombosiscanpresentacutelyor,muchmorecommonly,inanindolentmanner.
Theacutepresentationincludesflankpain,grosshematuria,andadeclineinrenalfunction..
Thromboembolism
Hypercoagulability
Hypovolemia
InterstitialedemaRenalperfusion↓ObstructionoftubularlumenRenalveinthrombosisNonsteroidalantiinflammatorydrugsAndotherdrugsPre-renalRenalfailureAcuteRenalFailurehypoalbuminemia,MalnutritionRetardationnegativenitrogenbalancehyperlipidemiaUrinarylossofhormones:vitamineD,T3andT4Edemaofthegastrointestinaltract:anorexiaandvomitInfectionImmunoglobin↓↓ThrombosisandemboliCardiovasculardiseaseeventsacceleratedatherosclerosisProteinmalnutrition
AmyloidosisLupusnephritisDiabeticnephropathyNephroticsyndromeassociatedmalignanceDifferentialDiagnosisRestDietary:sodiumandwaterrestriction(approximately3g/day)DiureticsLowerintraglomerularpressureStatintherapydonotrecommendroutineprophylacticanticoagulation.Generaltherapy(Nonimmunosuppressivetherapies
)TreatmentImmunosuppressivetherapyTreatmentGlucocorticoidsOtherimmunosuppressiveagents
—
Cyclophosphamide
orcyclosporineA
aloneorincombinationwithprednisonforrelapsing,glucocorticoid-dependentdiseaseorglucocorticoid-resistdisease.Dailyoralprednisone
(1mg/kgperdaytoamaximumof80mg/day)Asingledoseuponawakening(usuallybetweesevenandnineAM)Someclinicianspreferalternate-dayprednisonefromthebeginningtominimizethetoxicityoflong-termdailyprednisone,ataninitialdoseof2mg/kgeveryotherday(toamaximumdoseof120mg)Minimumofeightweeks,maximumduration
is16weeksSlowtaperingisperformedbothtosustaintheremissionandtoavoidadrenalsuppressionGlucocorticoidtherapyResponsetoGlucocorticoidtherapy
Acompleteremissionisareductioninproteinuriato300mg/day.Apartialresponseisareductioninproteinuriaof50percent,withabsolutevaluesbetween300mgand3.5g/day.Arelapseisreturnofproteinuriatoapproximately3.5gm/dayinpatientswhohadpreviouslyundergoneacompleteorpartialremission.Glucocorticoid-dependencereferstorelapsewhilerequirementforcontinuationofsteroidstomaintainremissionGlucocorticoid-resistancereferstolittleornoreductioninproteinuriaafter16weeksofadequateprednisone
therapy.Infectiousdisease:HeightenedriskoftypicalinfectionsOpportunisticinfections:HerpeszosterEndocrine:DiabetesmellitusBone:Osteoporosis
Gastrointestinal:Pepticulcerdisease,Pancreatitis,UGBEye:Elevatedintraocularpressure/glaucoma,ExophthalmosCardiovascular:HypertensionDermatologicandsofttissue:Skinthinningandpurpura,Cushingappearance,Acne.Majorsideeffectsassociatedwithcorticosteroidtherapy
Cyclophosphamide(CTX)
Azathioprine
(AZA)
Cyclosporine
(CysA)
Mycophenolate(MMF)
Tacrolimus(FK506)ImmunosuppressiveagentsNotthefirstchoiseanddon’tusealoneFrequentlyrelapsing,glucocorticoid-dependentorglucocorticoid-resistcasesImmunosuppressiveagentsA12-weekcourseof2mg/kgperdayofcyclophosphamide
Cumulativedoseof168mg/kgNeutropeniaandinfection—BonemarrowsuppressionGonadaltoxicity—atotaldosegreaterthan200to300mg/kgforCTX,Malignancy—acutelymphoblasticleukemia.AlopeciaandhemorrhagiccystitisLiverfunctioninjury.Otherscyclophosphamide-mostcommonlyuse
AlkylatingagentsCyclosporineatadoseof3to5mg/kgperdaytomaintainwholebloodtroughlevelsof100to200μg/LatleastsixmonthsCyclosporinesolutioncanbemixedwithmilk,chocolatemilk,ororangejuice(butnotgrapefruitjuice)atroomtemperature.Tacrolimusis0.05mg/kgperdaytomaintainwholebloodtroughlevelsbetween3and5μg/L.Thedosemaybeincreasedtoachieveahighertroughlevelbetween5and8μg/L,ifthereisnoreductioninproteinuriabytwomonths,providingtherenalfunctionhasnotworsened.
DOSAGEANDADMINISTRATIONCalcineurininhibitorsNephrotoxicity
—Hypertension
—
causedbyrenalvasoconstrictionandsodiumretention,Neurotoxicity—
severeheadache,visualabnormalities,andseizuresMetabolicabnormalities
—
GlucoseintoleranceInfections
—
Bacterial,viralandfungalinfectionsRiskofmalignancy
Othersideeffects
—
Gastrointestinalsideeffectsincludeanorexia,nausea,vomiting,diarrheaandabdominaldiscomfort
AdverseeffectassociatewithCalcineurininhibitorsThetargetdosageofMMFisgenerallybetween1.5to2gramsdaily.Startingwithlowerdosesatfirst(eg,500mgdailyforseveraldays)mayimprovepatients'gastrointestinaltoleranceofMMFAdverseeffect:Bonemarrowsuppression:cytopenias,requireregularmonitoringGastrointestinal
—
nearly75percentinitiallyhadgastrointestinal(GI)symptoms,includingnausea,diarrhea,andabdominalcramping.ThesesymptomsweretoleratedbetterwithtimeMycophenolatemofetil:
(MMF)
Treatedwithheparin
followedbywarfarinThegoalINRis1.5to2.0Durationofanticoagulation
—
Warfarin
therapyisgivenforaminimumof6to12months.Aslongasthepatientremainsnephrotic.Serumalbuminbelow2.0g/dL(20g/L)OptimaltherapyofhypercoagulabilityLotension,Losartan,Vasartan
,etclowerintraglomerularpressure,reductioninproteinexcretion,slowtherateofdiseaseprogression.Itisnotdependanttotheantihypertensiveeffect.Itispositivelyrelatedtothedoseofdrug.ACEI
and
ARBAcuterenalfailureHyperkalemiaNotices:Hypovolummia,useNSAIDtogetherSideeffectsPathologyIncidenceInfectionHematuriaHypertensionRenalinjuryTreatmentPrognosisMCDchildren(75%)commonlyseen---90%steroidsgoodFSGS5-15%younger+(65%)+(30%)+(10%)1/3
sensitive,dependentandresistrespectively
about10yearstoESRDMsPGN30%youngerandadult+++normalsomesensitive,somenotaccordingpathologyMembranousGNelderlyrarerareSteroid+cytotoxic1/4spontaneousremissions,progressslowlyMPGNyounger+grosshematuria+++(25%)resistpoorClinicalFeaturesandPathologyofPrimaryNephroticSyndrome20percentofcasesofsteroid-resistantNSareduetomutationsoftheNPHS1,NPHS2,WT1gene.Inpatientswithsteroid-resistantNSduetogenemutation,
wedonotrecommendimmunosuppressivetherapyOptimaltreatmentofSRNSnotduetoageneticdisorderis
unknown,Acombinationofcyclosporine
andprednisoneisrecommended,.Alternatively,cyclophosphamide,andtacrolimus
havealsobeenused.Hotpoints1:AboutFSGSSecondaryGlomerularDisease–-SecondarynephroticsyndromeWhytalkaboutdiabeticnephropathy?MostcommonsinglecauseESRDintheUS,Europe,andJapan17milliondiabeticsintheUS20-30%diabetics(bothtypeIandtypeII)developdiabeticnephropathy40%ESRDinUSrelatedtodiabeticnephropathyDefinitionAmicrovascularcomplicationofdiabetesmarkedbyalbuminuria,elevatedbloodpressure,andadeterioratingcoursefromnormalrenalfunctiontoESRD.ClinicalfeaturesGraduallyprogressiveproteinuriaMicroalbuminuriaisfirstclueBlandurinesediment–noRBCs,casts,etcGraduallydecreasingGFRPatientsasymptomatic,butdevelopworseninghypertensionNature
courseClinicalStagesofDN(Type1)1ststage:Renalenlargementandhyperfiltration2ndstage:Reversemicroalbuminuria,UAEisnormal(5-15).3rdstage:Microalbuminuria,incipientnephropathy(6-15Y)20-199ug/min30-299mg/24hcollection4thstage:Macroalbuminuria,overtnephropathy(10-15Y)>200ug/min>300mg/24hcollection5thstage:Progressiverenalfailureandsevereproteinuria(15-25Y)HowtodistinguishfromanotherkidneydiseaseLikelydiabetes:MacroalbuminuriaMicroalbuminuria,andPresenceofdiabeticretinopathyType1diabetesforatleast10yearsNoactiveurinarysedimentLikelyanothercauseofCKD:AbsenceofretinopathyRapidlydecreasingGFRhematuriaRefractoryhypertensionSignsorsxofothersystemicdiseaseTreatmentEarlyscreening TightglycemiccontrolHTNmanagementUseACEIasfirstline,ifnottolerated,useARB.UsethemaximumdoseastoleratedLupusnephritisSystemiclupuserythematosus(SLE)isamultisystem,autoimmuneds.withantibodiesdirectedagainstawidevarietyofcellularcomponentsLupusnephritisisoneofthemostseriousmanifestationsof(SLE).Frequency,race,sexandage
TheprevalenceofSLEis1caseper2000inthegeneralpopulation.SLEismorecommoninblackpeople,HispanicpeopleandAsianthaninwhitepeople.lupusnephritismorecommoninfemalesandtypicallyoccursinpatientsaged20-40years;clinicalrenaldiseasewithaworseprognosisismorecommoninmaleswithSLE.
ClinicalfeaturesVariousorgansystemsareeffected,likeskin,joints,serousmembranes,heart,neurologic,bloodandthekidneys.Rash,oralornasalulcers,synovitis,fatigue,fever,arthritis,serositis,edema,etc.ClinicalsignsLaboratoryStudiesTestsofSLEdiseaseactivityDiseaseactivity:ANA,anti-dsDNA,C3,C4,andCH50
,ESRorCRP.Creatine,urea,urialysisRenalbiopsyisusefulindeterminingprognosisandtreatment.IF:Fullhouse.LupusNephritisStageFeaturesStageINormallookingglomeruliStageIIMesangialexpansionStageIIIFocalproliferative<50%StageIVDiffuseProlif.>50%stageVMembranousStageVIAdv.sclerosinglesionsPathologyoflupusnephritisTreatmentLupusnephritiscantransformfromoneclasstotheotheroverthecourseofthedisease.CorticosteroidtherapyshouldbeinstitutedClassIV(themostaggressiveform)isusuallytreatedwithsteroidsandcyclophosphamide.OtherimmunosuppressantlikeMMF,cyclosporinehasbeenusedinthesecases.Treathypertensionaggressively.Preventosteoporosisetc.AmyloidosisAmyloidosisisaclinicaldisordercausedbyextracellulardepositionofinsolubleabnormalfibrilsthatinjuretissue.AmyloidosisALamyloid(primaryamyloid)associatedwithplasmacelldisorders,mostlyovertmyelomaAAamyloid(secondaryamyloid)isanacutephasereactantassociatedwithchronicinflammatorydiseasesliketuberculosis,osteomyelitis,rheumatoidarthritisandbronchiectasisMorecommoninelderlyTheamyloidisaneosinophilicextracellularsubstance,Congoredstainpositiveandblue-greenbirefringence.AmyloidosisArangeofclinicalpresentationswithrenal,heart,gastrointestine,localdepositionandotherproblemsRenalfailureandnephroticrangeproteinuriaarethemostcommonrenalpresentationAbnormalelevatingofMonoclonalIginbloodandlightchains(BenceJones)inurineinALamyloid.Relatedrenaldisordersincludelightchaindepositdisease,fibrillaryGNandimmunotactoidGNPrognosisforispoor.MonoclonalpatternSPEPUrinarymonoclonalproteinPanelB:Adense,localizedband(redasterisk)representingamonoclonalproteinofgammamobilityisseenonserumproteinelectrophoresisonagarosegel(anodeonleft).PanelA:Densitometertracingofthesefindingsrevealsatall,narrow-basedpeak(redasterisk)ofgammamobilityandareductioninthenormalpolyclonalgammaband.Themonoclonalbandhasadensitometricappearancesimilartothatofalbumin(alb),andhasbeenlikenedtoachurchspire.PanelB:Thisfigureillustratesthecelluloseacetateelectrophoreticpatternofaurinesample.Itrevealsadensebandofproteinwithbetamobility.PanelA:Densitometertracingshowsatall,narrow-basedpeakofbetamobility.Thesefindingsareconsistentwithaurinemonoclonalprotein(BenceJonesprotein);NormalpatternofSPEPCLINICALMANIFESTATIONSRenaldisease
—
asymptomaticproteinuriaorclinicallyapparentnephroticsyndromeCardiomyopathy
—
systolicordiastolicdysfunctionandheartfailure.syncopeduetoarrhythmiaheartblock,andanginaorinfarctionduetoaccumulationofamyloidinthecoronaryarteries.Gastrointestinaldisease
—
Hepatomegalywithorwithoutsplenomegaly.Bleeding,gastroparesis,constipation,etc.Neurologicabnormalities
—
Mixedsensoryandmotorperipheralneuropathyand/orautonomicneuropathyMusculoskeletaldisease
—pseudohypertrophy,alargetongueHematologicabnormalities
—bleedingdiathesis,factorXdeficiencySkinmanifestations
—waxythickening,easybruising,andsubcutaneousnodulesorplaques.Purpura,inaperiorbitaldistribution(raccooneyes).Others:Pulmonary,visualabilityLightmicrographofglomerularamyloidosisshowsnodular,amorphousmaterial(arrows)extendingfromthemesangiumintothecapillaryloopsandnarrowingorclosingthecapillarylumens.ThenodulesaremoreamorphousthanthoseseenindiabeticnephropathybutdemonstrationofamyloidfibrilsonelectronmicroscopyordemonstratinggreenbirefringenceonCongoredstainingisrequiredtoconfirmthediagnosis.CourtesyofHelmutRennke,MD.
Congoredstainviewedunderpolarizedlightofarenalbiopsyfromapatientwithrenalamyloidosis.Greenbirefringence(whitearrows)ofinterstitialamyloiddepositscanbeseen.CourtesyofHelmutRennke,MD.
Electronmicrographshowingexpansionofthemesangiumbyamyoidfibrilsmeasuringbetween9and11nanometersindiameter.Thefibrillarappearanceisbestappreciatedatthearrow.Thesefibrilsaresmallerthanthoseseeninfibrillaryglomerulonephritis.CourtesyofHelmutRennke,MDRenaltubularamyloidosisAmyloidosiswithmarkeddepositioninthetubularbasementmembranesonlightmicroscopy(leftpanel,arrows).TheamyloiddepositsshowgreenbirefringencewhenviewedunderpolarizedlightwithCongoredstain(rightpanel).CourtesyofHelmutRennke,MD.OutcomeSurvivalfromonsetofsymptomsvariesfrom1moto10yr.Therateofdiseaseprogressionisvariableanddependsontheextentoforganinvolvement.Henoch-Sch?nleinpurpuranephritisHSPisasmall-vesselvasculitischaracterizedbypurpura,
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 網(wǎng)絡(luò)公開課企業(yè)制定與實(shí)施新質(zhì)生產(chǎn)力戰(zhàn)略研究報告
- 2025年國土資源普查核儀器項(xiàng)目建議書
- 醫(yī)學(xué)專家中介合同(2篇)
- 區(qū)域冷庫建設(shè)招標(biāo)合同(2篇)
- 校長在班主任素質(zhì)大賽培訓(xùn)會上的講話稿范文
- 2025年醫(yī)用真空負(fù)壓機(jī)項(xiàng)目合作計(jì)劃書
- 小學(xué)家長委員會籌備計(jì)劃
- 利用多媒體技術(shù)增強(qiáng)文化遺產(chǎn)教育效果-全面剖析
- 無人配送技術(shù)革新-全面剖析
- 人工智能在制造環(huán)節(jié)的應(yīng)用-全面剖析
- 勞動法與社會保障法課程教學(xué)大綱
- 數(shù)字取證的云計(jì)算取證技術(shù)
- AI在藥物研發(fā)中的應(yīng)用
- 第20課國民革命與南京政府的統(tǒng)治【中職專用】(高教版2023基礎(chǔ)模塊)
- 安全生產(chǎn)檔案管理的培訓(xùn)指導(dǎo)
- 【復(fù)習(xí)資料】10633工程造價管理(習(xí)題集及答案)
- 鉤蟲病護(hù)理課件
- 維生素D在兒科的應(yīng)用課件
- 形勢與政策(吉林大學(xué))智慧樹知到課后章節(jié)答案2023年下吉林大學(xué)
- 質(zhì)量控制計(jì)劃QCP
- 納稅人進(jìn)項(xiàng)稅額分?jǐn)偡绞絺浒笀蟾姹?樣本)
評論
0/150
提交評論